Bio-Techne Corporation (TECH)’s Financial Results Comparing With Molecular Templates Inc. (NASDAQ:MTEM)

Bio-Techne Corporation (NASDAQ:TECH) and Molecular Templates Inc. (NASDAQ:MTEM) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Techne Corporation 681.71M 10.47 96.31M 2.46 63.16
Molecular Templates Inc. 9.42M 18.29 30.57M -1.13 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Bio-Techne Corporation and Molecular Templates Inc.


Table 2 represents Bio-Techne Corporation (NASDAQ:TECH) and Molecular Templates Inc. (NASDAQ:MTEM)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Bio-Techne Corporation 14.13% 12% 7.7%
Molecular Templates Inc. -324.52% -38.6% -29.9%

Risk & Volatility

Bio-Techne Corporation has a beta of 1.01 and its 1.00% more volatile than Standard & Poor’s 500. Molecular Templates Inc.’s 3.15 beta is the reason why it is 215.00% more volatile than Standard & Poor’s 500.


4.6 and 3.5 are the respective Current Ratio and a Quick Ratio of Bio-Techne Corporation. Its rival Molecular Templates Inc.’s Current and Quick Ratios are 2.8 and 2.8 respectively. Bio-Techne Corporation has a better chance of clearing its pay short and long-term debts than Molecular Templates Inc.


Bio-Techne Corporation shareholders receive an annual dividend of $1.28 per share which is subject to 0.69% dividend yield. Molecular Templates Inc. does not pay a dividend.

Analyst Ratings

Bio-Techne Corporation and Molecular Templates Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bio-Techne Corporation 0 2 2 2.50
Molecular Templates Inc. 0 0 0 0.00

Bio-Techne Corporation has a -0.29% downside potential and a consensus price target of $188.5.

Institutional & Insider Ownership

Roughly 96.6% of Bio-Techne Corporation shares are held by institutional investors while 70.8% of Molecular Templates Inc. are owned by institutional investors. Insiders held roughly 0.4% of Bio-Techne Corporation’s shares. Comparatively, insiders own roughly 0.7% of Molecular Templates Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bio-Techne Corporation -3.59% -12.9% -20.41% -3.29% 20.74% 20.13%
Molecular Templates Inc. -15.73% -15.07% -3.98% -27.3% -38.53% -56.69%

For the past year Bio-Techne Corporation had bullish trend while Molecular Templates Inc. had bearish trend.


Bio-Techne Corporation beats on 12 of the 13 factors Molecular Templates Inc.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.